Personalized Neoantigen Peptide Vaccine not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “This is a personalized cancer vaccine made of 10-20 synthetic long peptides derived from the unique mutations (neoantigens) found in a patient's tumor. Each vaccine is custom-formulated based on whole exome and RNA sequencing of tumor and normal tissue. The peptides are administered intramuscularly in combination with poly-ICLC (Hiltonol) as an adjuvant to enhance immune response. The…”In the company’s words, NCT07002203 on ClinicalTrials.gov
- Tested for
- Solid Tumors, Advanced Cancer, Recurrent Cancer, Neoantigen-Specific Immunotherapy, Personalized Cancer Vaccine
- Main trialPhase 1/2
- “This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is to help the patient's immune system recognize and attack their cancer. The study will enroll adult patients (20 years or older) who have solid tumors that meet specific stage-related criteria. These include advanced cancers that are resistant to prior treatments and early-stage cancers at high risk of recurrence,…”In the company’s words, NCT07002203 on ClinicalTrials.gov
Other drugs for Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Aug 2027 | Personalized Neoantigen Peptide Vaccines for Solid Tumors | |
| Phase 1/2Completed | 15 Aug 2025 | Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026